Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma
Frontiers in Cell and Developmental Biology · 04.06.2026 · 14
DOI: 10.3389/fcell.2026.1765945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 04.06.2026. Verfasst von Amaya Lopez-Pascual und 22 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Epigenetic alterations play an increasingly recognized role in carcinogenesis and in the development of resistance to anticancer therapies. Epigenetic enzymes (writers and erasers) and effectors (readers) are largely influenced by the availability of metabolites generated through one-carbon metabolism (OCM), the tricarboxylic acid (TCA) cycle, and acetyl-CoA synthesis (ACS). In this study we examined the expression of epigenetic and metabolic genes to investigate their interplay in cholangiocarcinoma (CCA).
Method
We examined 257 epigenetic genes (EpiGs), 96 metabolic genes (MGs), and 189 rate-limiting enzymes (RLEs) in transcriptomic data from iCCA, eCCA, and normal bile ducts, healthy liver-derived organoids, and CCA tumoroids, alongside prognostic signatures. CRISPR-Cas9 DepMap data evaluated the impact of EpiGs and MGs on cell viability. HuCCT-1 iCCA cells were exposed to hypoxia (1% O 2 , 24 h) to assess EpiG responses. Transcriptomic deconvolution characterized EpiGs, MGs, and RLEs expression across four tumor microenvironment (TME) subtypes. Two mouse CCA models (TAZ/Akt and NICD1/Akt) underwent RNA-seq, complemented by multi-omic profiling (transcriptomic, proteomic, metabolomic) in TAZ/Akt livers.
Results
Several EpiGs were upregulated in iCCA and eCCA, including writers ( DNMT1 , EZH2 , SUZ12 ), readers ( CBX3 , PHF20L1 , SMARCA4 ), and erasers ( HDAC1 , HDAC3 , KDM5C ). MGs in OCM, TCA, and ACS pathways were dysregulated (up: GART , IDH2 , TYMS ; down: ALDH1L1 , MAT1A , SHMT1 ). Integrated analyses identified 27 EpiGs and 8 MGs whose overexpression predicted poor survival. Subsets of EpiGs, MGs, and RLEs were linked to proliferative, high-recurrence iCCA subclasses. CRISPR screens highlighted 50 EpiGs and 23 MGs essential for CCA viability. Tumor microenvironment (TME) analyses revealed distinct immune-stromal subclasses with coherent epigenetic-metabolic signatures. In CCA cells, hypoxia induced epigenetic programs that mirrored those in CCA patients. Transcriptomic analyses in human and multi-omic analyses (transcriptomic, metabolomic, and proteomic studies) in mouse CCA livers highlighted rewiring of nucleotide, one-carbon, lipid, and mitochondrial pathways, with evidence of metabolic-epigenetic crosstalk.
Conclusion
EpiGs and MGs are markedly altered in both human and experimental CCA, with several changes particularly enriched in aggressive molecular subclasses associated with poor prognosis. We observed substantial rewiring of epigenetic cofactor-related MG expression in CCAs. Functional assays validated new targets among EpiGs (e.g., CBX3 , CHD4 , DEK , SMARCA4 , and TRIM28 ) and MGs ( TYMS and IDH2 ) in CCA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
- Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain.
- CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
- Universidad de Guadalajara, Centro Universitarios de los Altos, Ciencias de la Salud, Guadalajara, México.
- Functional Proteomics Laboratory, Centro Nacional de Biotecnología, CSIC, Madrid, Spain.
- Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.
Zitieren
APA
Lopez-Pascual, A., Elurbide, J., Valbuena-Goiricelaya, E., Latasa, M. U., Anaya, E., Adan-Villaescusa, E., Castelló-Uribe, B., Martínez-Pérez, L. A., Uriarte, I., Arechederra, M., Ciordia, S., Corrales, F. J., Strnad, P., Frankova, S., Sticova, E., Fabian, O., Colyn, L., Inacio, P., Bayo, J., …, & Avila, M. A. (2026). Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1765945
Vancouver
Lopez-Pascual A, Elurbide J, Valbuena-Goiricelaya E, Latasa MU, Anaya E, Adan-Villaescusa E, et al. Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1765945
BibTeX
@article{LopezPascual2026,
author = {Lopez-Pascual, Amaya and Elurbide, Jasmin and Valbuena-Goiricelaya, Emiliana and Latasa, M Ujue and Anaya, Elena and Adan-Villaescusa, Elena and Castelló-Uribe, Borja and Martínez-Pérez, Luz A and Uriarte, Iker and Arechederra, Maria and Ciordia, Sergio and Corrales, Fernando J and Strnad, Pavel and Frankova, Sona and Sticova, Eva and Fabian, Ondrej and Colyn, Leticia and Inacio, Patricia and Bayo, Juan and Huch, Meritxell and Berasain, Carmen and Fernández-Barrena, Maite G and Avila, Matías A},
title = {Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
volume = {14},
doi = {10.3389/fcell.2026.1765945}
}
EUVIMED